AZN core EPS of $2.63 surpasses expectations by $1.36 as oncology sales fuel revenue growth of 5% year over year.
AstraZeneca posted second-quarter core earnings per share of $2.63, beating Wall Street estimates by $1.36. The outperformance was driven by robust sales of its cancer treatments, a key growth segment for the company.
Revenue rose 5% year over year at constant exchange rates, aligning with prior guidance. Analysts had anticipated a softer print, with consensus estimates pegged at $1.27 per share for the quarter.
The results underscore the strength of AstraZeneca’s oncology portfolio, which continues to offset weaker performance in other therapeutic areas.